A novel TNKS/USP25 inhibitor blocks the Wnt pathway to overcome multi-drug resistance in TNKS-overexpressing colorectal cancer.

Authors:
Zhu H; Gao Y; Liu L; Tao M; Lin X and 12 more

Journal:
Acta Pharm Sin B

Publication Year: 2023

DOI:
10.1016/j.apsb.2023.10.013

PMCID:
PMC10793098

PMID:
38261825

Journal Information

Full Title: Acta Pharm Sin B

Abbreviation: Acta Pharm Sin B

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest The authors declare no potential conflicts of interest."

Evidence found in paper:

"This study was financially supported by the National Key Research and Development Program of China (2022YFC2804100, 2021YFF0502400, 2022YFC2804300); National Natural Science Foundation of China (82073713, 22137006, 82104033, 82173730, 81903499, 32070070, 82160669); Innovative research team of high-level local universities in Shanghai (SHSMU-ZDCX20212702, China). We thank Dr. Juncheng Su from Shanghai Jiao-Tong University School of Medicine (Shanghai, China) for providing the LoVo and COLO 320DM cell lines."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025